Zentalis logo.png
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 18:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis logo.png
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 28, 2024 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis logo.png
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
February 27, 2024 07:00 ET | ZENTALIS PHARMACEUTICALS
Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer...
Zentalis logo.png
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
February 13, 2024 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis logo.png
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024 17:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis logo.png
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
January 25, 2024 07:00 ET | ZENTALIS PHARMACEUTICALS
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business...
Zentalis logo.png
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2024 16:49 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis logo.png
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023 17:39 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis logo.png
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
November 09, 2023 07:00 ET | ZENTALIS PHARMACEUTICALS
Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th,...
Zentalis logo.png
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
November 06, 2023 07:18 ET | ZENTALIS PHARMACEUTICALS
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...